Hologic, Inc. (NASDAQ:HOLX) is set to issue its quarterly earnings data after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of $0.49 per share for the quarter.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business had revenue of $806.10 million during the quarter, compared to analyst estimates of $799.70 million. During the same quarter last year, the firm earned $0.51 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, analysts expect Hologic to post $2.01 EPS for the current fiscal year and $2.14 EPS for the next fiscal year.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at 37.85 on Wednesday. The firm has a market cap of $10.62 billion, a price-to-earnings ratio of 14.10 and a beta of 0.91. The stock has a 50 day moving average price of $37.20 and a 200-day moving average price of $41.41. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80.

A number of brokerages have weighed in on HOLX. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $51.00 price target on shares of Hologic in a research report on Friday, July 14th. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research report on Tuesday. Deutsche Bank AG cut their price objective on Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. Bank of America Corporation reissued a “neutral” rating and set a $48.00 price objective (up previously from $44.00) on shares of Hologic in a research report on Friday, July 21st. Finally, Barclays PLC reissued an “overweight” rating and set a $53.00 price objective (up previously from $50.00) on shares of Hologic in a research report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. Hologic currently has a consensus rating of “Buy” and a consensus target price of $47.77.

In related news, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total transaction of $278,706.56. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total value of $276,908.24. Following the transaction, the director now owns 23,810 shares in the company, valued at $955,257.20. The disclosure for this sale can be found here. Insiders have sold 30,775 shares of company stock worth $1,175,662 over the last 90 days. Corporate insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/11/01/hologic-inc-holx-scheduled-to-post-quarterly-earnings-on-wednesday.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.